Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants

A small study assessed the neutralization of pseudoviruses composed of the recombinant deltacron and omicron BA.3 variants. BA.3 did not show broad cross-resistance, but deltacron was largely resistant to immune response elicited either by three doses of mRNA vaccines or by previous infection.

Saved in:
Bibliographic Details
Published inNew England Journal of Medicine Vol. 386; no. 24; pp. 2340 - 2342
Main Authors Evans, John P., Qu, Panke, Zeng, Cong, Zheng, Yi-Min, Carlin, Claire, Bednash, Joseph S., Lozanski, Gerard, Mallampalli, Rama K., Saif, Linda J., Oltz, Eugene M., Mohler, Peter J., Gumina, Richard J., Liu, Shan-Lu
Format Journal Article Web Resource
LanguageEnglish
Published United States Massachusetts Medical Society 16.06.2022
Subjects
Antibodies
Antibodies, Neutralizing - immunology
Antibodies, Viral
Coronavirus
Coronaviruses
Correspondence
COVID-19 - immunology
COVID-19 - therapy
COVID-19 - virology
COVID-19 vaccines
Cross-resistance
Hospitalization
Humans
Immune response
Infectious Disease
Intensive care
mRNA
Mutation
Neutralization Tests
Pandemics
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - immunology
Vaccines
Viral Infections
United States > US
Ohio
Online AccessGet full text

Cover

More Information
Summary:A small study assessed the neutralization of pseudoviruses composed of the recombinant deltacron and omicron BA.3 variants. BA.3 did not show broad cross-resistance, but deltacron was largely resistant to immune response elicited either by three doses of mRNA vaccines or by previous infection.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2205019